Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pharmacogenetics of anticancer monoclonal antibodies.

Cancer drug resistance (Alhambra, Calif.)·2022

Same author

Occult metastatic thyroid cancer diagnosed during breast cancer axillary sentinel node biopsy.

Endocrinology, diabetes & metabolism case reports·2020

Same author

A novel CASR mutation (p.Glu757Lys) causing autosomal dominant hypocalcaemia type 1

Endocrinology, diabetes & metabolism case reports·2018

Same author

Ultrarapid clozapine metabolism and CYP2D6 gene duplication in a patient with schizophrenia.

Personalized medicine·2018

Same author

Higher than expected clozapine serum level and clozapine/norclozapine ratio due to CYP450 gene polymorphisms.

Personalized medicine·2018

Same author

ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine.

Pharmacogenomics and personalized medicine·2017

Search research articles

Related Experiment Video

Updated: May 27, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Warfarin toxicity and individual variability-clinical case.

Irina Piatkov¹, Colin Rochester, Trudi Jones

¹Diversity Health Institute, DHI Laboratory, ICPMR level 2, Sydney-West Area Health Service, Westmead Hospital, Westmead, NSW 2145, Australia. irina.piatkov@swahs.health.nsw.gov.au

|November 10, 2011

Summary

Warfarin toxicity risk is increased by genetic factors and drug interactions. Personalized medicine approaches can reduce uncertainty in interpreting toxicity and health risks.

Keywords:

anticoagulant pesticides warfarin

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Experiment Videos

Last Updated: May 27, 2026

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Area of Science:

Pharmacology
Toxicology
Genetics

Background:

Warfarin is a critical anticoagulant for thrombosis prevention and treatment.
Warfarin and its derivatives are also used as pesticides.
Several factors contribute to the risk of warfarin toxicity.

Observation:

Polymorphisms in cytochrome P450 genes and drug interactions are primary drivers of warfarin toxicity.
Individual susceptibility to toxic agents varies significantly.
Genetically determined metabolic capacity influences warfarin and metabolite levels, especially critical for narrow therapeutic index drugs.

Findings:

Genetic variations and drug interactions significantly elevate the risk of warfarin toxicity.
Understanding individual metabolic capacity is crucial for accurate toxicity assessment.
Personalized interpretation can mitigate scientific uncertainties in toxicity cases.

Implications:

Personalized medicine offers a pathway to more accurate warfarin toxicity assessment.
Tailoring warfarin therapy based on individual genetics can improve patient safety.
This approach has the potential to reduce adverse events associated with warfarin use.